The inclusion of biomarkers such as PD-L1 expression and gene expression profiling (GEP) alongside tumour mutational burden (TMB) can address the limitations of TMB as a standalone predictor, particularly in cancers like breast and prostate. This evidence concerns the gene CD274 and neoplasm.